Many tumor cells rely on aerobic glycolysis instead of oxidative phosphorylation for their continued proliferation and survival. Myc and HIF-1 are believed to promote such a metabolic switch by, in part, upregulating gene expression of pyruvate dehydrogenase (PDH) kinase 1 (PDHK1), which phosphorylates and inactivates mitochondrial PDH and consequently pyruvate dehydrogenase complex (PDC). Here we report that tyrosine phosphorylation enhances PDHK1 kinase activity by promoting ATP and PDC binding. Functional PDC can form in mitochondria outside of the matrix in some cancer cells and PDHK1 is commonly tyrosine phosphorylated in human cancers by diverse oncogenic tyrosine kinases localized to different mitochondrial compartments. Expression of phosphorylation-deficient, catalytic hypomorph PDHK1 mutants in cancer cells leads to decreased cell proliferation under hypoxia and increased oxidative phosphorylation with enhanced mitochondrial utilization of pyruvate and reduced tumor growth in xenograft nude mice. Together, tyrosine phosphorylation activates PDHK1 to promote the Warburg effect and tumor growth.
INTRODUCTION
Normal cells produce ATP in the mitochondria through oxidative phosphorylation, whereas under hypoxia, glucose is converted to lactate to produce ATP. In contrast, the Warburg effect describes that cancer cells take up more glucose than normal tissue and favor aerobic glycolysis (Kroemer and Pouyssegur, 2008; Vander Heiden et al., 2009; Warburg, 1956) . In normal cells, pyruvate dehydrogenase (PDH) A1 catalyzes the conversion of pyruvate to acetyl-CoA, which, along with the acetylCoA from the fatty acid b-oxidation, enters into the Krebs cycle to produce ATP and electron donors including NADH. PDHK1 is a Ser/Thr kinase that negatively regulates PDHA1 activity by phosphorylating PDHA1. This occurs in the pyruvate dehydrogenase complex (PDC) (Roche et al., 2001) . PDC is organized around a 60-meric dodecahedral core formed by acetyltransferase (E2p) and E3-binding protein (E3BP) (Hiromasa et al., 2004) , which binds PDH (aka E1p), PDHK, dihydrolipoamide dehydrogenase (E3), and pyruvate dehydrogenase phosphatase (PDP) (Read, 2001 ). There are four PDHK isoforms (1-4) identified in humans. PDHKs are recruited to PDC through binding to the inner lipoyl (L2) domain of the E2p subunit in the E2p/E3BP core (Liu et al., 1995) . This enhances PDHK activity by granting PDHK access to its substrate PDH, which binds to the E1-binding domain that is immediately downstream of L2 of E2p. Phosphorylation of PDH by PDHK results in the inactivation of PDC, while dephosphorylation by PDP restores PDC activity (Roche et al., 2001) .
In cancer cells, however, pyruvate is converted to lactate regardless of the presence of oxygen. This may be in part due to upregulation of PDHK activity and/or inhibition of PDH in cancer cells. PDHK1 is believed to be upregulated by Myc and HIF-1 to achieve functional inhibition of mitochondria by phosphorylating and inactivating PDH in cancer cells (Kim et al., 2007; Papandreou et al., 2006) . Recent studies revealed that targeting PDHK by dichloroacetate (DCA) shifts cancer cell metabolism from glycolysis to oxidative phosphorylation and inhibits tumor growth (Bonnet et al., 2007) . This finding suggests that the PDHK/PDH axis may contribute to cancer cell metabolism and tumor growth.
However, how oncogenic signals activate PDHK1 to regulate cancer cell metabolism still remains unclear. Here we report that oncogenic tyrosine kinases are localized to the mitochondria in cancer cells, where they phosphorylate and activate the mitochondrial Ser/Thr kinase PDHK1 to promote cancer cell metabolism and tumor growth.
RESULTS

Mitochondrial PDHK1 Is Tyrosine Phosphorylated and Activated by FGFR1 in Cancer Cells
To better understand how tyrosine kinase signaling, commonly upregulated in tumors, regulates the Warburg effect, we examined whether oncogenic FGFR1 phosphorylates and regulates PDHK1 ( Figure 1A ). We found that active, recombinant FGFR1 (rFGFR1) effectively phosphorylates purified GST-tagged PDHK1 in an in vitro kinase assay ( Figure 1B) . Further mass spectrometric analysis identified three tyrosine residues of PDHK1, including Y136, Y243, and Y244, that are phosphorylated by FGFR1 ( Figure 1A ) (numbering of PDHK1 is as per SWISS-PROT entry Q15118). In addition, GST-tagged PDHK1 was tyrosine phosphorylated in 293T cells transiently cotransfected with FGFR1 wild-type (WT), but not in cells coexpressing a kinase dead (KD) form of FGFR1 (Figures 1C, lower, and 1D) . Moreover, in an in vitro PDHK1 kinase assay, tyrosine-phosphorylated GST-PDHK1 from cells coexpressing FGFR1 WT but not FGFR1 KD demonstrated enhanced kinase activity and effectively phosphorylated recombinant PDHA1 as a substrate (Figure 1C, upper) .
Overexpression of FGFR1 or its mutational activation have been implicated in various human solid tumors, including breast cancer, pancreatic adenocarcinoma, and malignant astrocytoma (Kobrin et al., 1993; Luqmani et al., 1992; Morrison et al., 1994; Penault-Llorca et al., 1995) . In addition, recurrent chromosomal translocations involving the FGFR1 gene on 8p11.2-11.1 are associated with stem cell myeloproliferative disorder (MPD), which results in expression of active FGFR1 fusion tyrosine kinases. We found that inhibition of FGFR1 by a small molecule inhibitor TKI258 results in decreased tyrosine phosphorylation levels of GST-PDHK1 in cells coexpressing FGFR1 WT ( Figure 1D , left). Similar results were obtained in TKI258-treated cells coexpressing GST-PDHK1 and ZNF198-FGFR1 4ZF, which is an active fusion tyrosine kinase associated with the t(8;13)(p11;q12) MPD (Xiao et al., 1998) (Figure S1 ). Interestingly, immunoblotting results show that FGFR1 as a receptor tyrosine kinase is colocalized with PDHK1 and its substrate PDHA1 in mitochondria ( Figure 1D , right). Moreover, TKI258 treatment significantly decreased phosphorylation levels of PDHA1 at S293 in human myeloid leukemia KG1a cells harboring a FOP2-FGFR1 fusion protein (Gu et al., 2006) (Figure 1E , left) and lung cancer NCI-H1299 cells overexpressing FGFR1 (Marek et al., 2009) (Figure 1E , right). In consonance with this, targeting PDHK1 by a PDHK inhibitor, dichloroacetate (DCA), or shRNA results in decreased S293 phosphorylation levels of PDHA1 in FGFR1-expressing cancer cells ( Figure 1F ).
FGFR1 Activates PDHK1 through Direct
Phosphorylation at Multiple Tyrosine Sites that Promotes ATP and PDC Binding to PDHK1 We next found that incubation with rFGFR1 results in increased tyrosine phosphorylation levels and kinase activity of GST-PDHK1 WT. However, although rFGFR1 phosphorylates all of the Y/F mutants, substitution of Y136, Y243, or Y244 attenuates the FGFR1-dependent increase of PDHK1 kinase activity assessed by S293 phosphorylation levels of PDHA1 proteins, while double mutation of both Y243 and Y244 abolishes the enhanced activation of PDHK1 by FGFR1 ( Figure 2A ).
As shown in Figure 2B , crystal structures of PDHK1 reveal that Y243 and Y244 are close to the ATP lid and ATP-binding site, suggesting that phosphorylation of these residues could affect ATP binding and PDHK1 catalytic activity. In contrast, Y136 is distal to both ATP and substrate binding sites of PDHK1, but is closer to the binding site of a small molecule drug, AZD7545, which inhibits PDHK1 and PDHK3 by aborting the kinase binding to the pyruvate dehydrogenase complex (PDC) scaffold (Kato et al., 2007) . Indeed, incubation with rFGFR1 led to increased [a- 32 P]ATP binding to PDHK1 WT and Y136F mutant. In contrast, substitution of Y243 and/or Y244 abolished the FGFR1-dependent enhancement of ATP binding to PDHK1 ( Figure 2C ). To determine whether Y136 phosphorylation affects the binding of PDHK1 to PDC, we incubated active rFGFR1 with purified GST-PDHK1 WT or Y/F mutants in an in vitro kinase assay, followed by incubation with whole-cell lysates from 293T cells. Phosphorylation of PDHK1 WT by FGFR1 resulted in increased binding between PDHK1 and PDC E2 protein, as well as enhanced association between PDHK1 and its substrate PDHA1, which exists in PDC. In contrast, substitution of Y136 abolished the enhanced association of PDHK1 to PDC E2 protein or PDHA1 in the presence of rFGFR1 ( Figure 2D ). Interestingly, substitution of Y243 and/or Y244 also led to abolishment of the FGFR1-dependent increased PDHK1/PDC E2 and PDHK1/PDHA1 associations ( Figure 2E ). These results together suggest that phosphorylation at both Y243 and Y244, but not Y136, may be required to promote ATP binding to PDHK1, which consequently facilitates PDHK1 binding to PDC scaffold to access substrate PDHA1. In contrast, Y136 phosphorylation may only function to enhance binding between PDHK1 and PDC. Figure S2 shows the results of analysis of the relative stability of proteins to limited proteolytic digestion with chymotrypsin (Kang et al., 2007) , which suggests the global structure of each mutant protein was not altered and decreased kinase activation ( Figure 3B ) or ATP/PDC-binding ability of PDHK1 Y/F mutants are not due to structural alterations.
Oncogenic FGFR1 Is Localized in Mitochondria in Cancer Cells, where It Phosphorylates PDHK1 Using an antibody that specifically recognizes PDHK1 phospho-Y243, we observed that rFGFR1 and FGFR1 WT phosphorylated GST-PDHK1 WT, Y136F, and Y244F mutants, but not the Y243F and Y243/244F mutants, at Y243 in an in vitro kinase assay using recombinant proteins ( Figure 3A ) and in 293T cells coexpressing these PDHK1 variants ( Figure 3B ), respectively. We also observed that inhibiting FGFR1 by TKI258 decreased PDHK1 Y243 phosphorylation in FGFR1-expressing H1299 lung cancer cells ( Figure 3C , left) and KG1a leukemia cells ( Figure 3C , right). TKI258 does not inhibit PDHK1 kinase activity in an in vitro kinase assay ( Figure S3A ). Moreover, knockdown of FGFR1 by shRNA in H1299 cells for 48 hr results in decreased phosphorylation levels of PDHK1 Y243 and PDHA1 S293 ( Figure 3D ). Further discussion regarding decreased PDHK1 protein levels in H1299 cells with long term knockdown of FGFR1 is provided in the Discussion section. (B) Active recombinant FGFR1 (rFGFR1) directly phosphorylates purified GST-tagged PDHK1 at tyrosine residues in an in vitro kinase assay. Phosphorylated rFGFR1 and GST-PDHK1 were detected by a specific phospho-Tyr antibody (pY99). (C) Purified GST-PDHK1 from cells coexpressing FGFR1 wild-type (WT), but not an FGFR1 kinase dead form (KD), shows increased kinase activity in an in vitro PDHK1 kinase assay using recombinant pyruvate dehydrogenase A (rPDHA) as a substrate (upper). Western blot revealed that GST-PDHK1 was tyrosine phosphorylated in cells with coexpression of FGFR1 WT but not KD mutant (lower). (D) Inhibition of FGFR1 by TKI258 (2 hr) results in decreased tyrosine phosphorylation levels of PDHK1 in cells coexpressing FGFR1 WT (left). Cells coexpressing FGFR1 KD and GST-PDHK1 were included as a negative control. Western blot result shows that FGFR1 is colocalized with PDHK1 and its substrate PDHA1 in mitochondria (right). We also detected a fraction of FOP2-FGFR1 fusion and FGFR1 in mitochondria along with mitochondrial PDHK1 and PDHA1 ( Figure 3E ) in KG1a and H1299 cells, respectively, with mitochondrial COX IV and cytosolic b-actin as control markers ( Figure 3F ). Figures S3B and 3C show no plasma membrane or nuclear contamination in the mitochondrial fractions. In consonance with these observations, immunofluorescence assay results show that FGFR1 is colocalized with the control mitochondrial marker MitoTracker Mitochondrion-Selective dyes, but not with nuclear marker DAPI in H1299 cells (Figures 3G and S4A) . Figure S4B shows no cross-reaction between FGFR1 antibody and MitoTracker Mitochondrion-Selective dyes. In addition, knockdown of FGFR1 by shRNA leads to decreased mitochondrial localization of FGFR1 in H1299 cells ( Figure 3G ), while stimulation of cells with FGFR1 ligand bFGF does not significantly alter the FGFR1 mitochondrial localization ( Figure S4C ).
We further investigated the ultrastructural localization of FGFR1 by immunogold transmission electron microscopy (TEM). Specific immunogold particles were found in mitochondria of H1299 cells. This immunogold particle distribution was not observed when the primary anti-FGFR1 antibody was omitted ( Figure 4A , left) and was greatly reduced by FGFR1 shRNA ( Figure 4A , right). To localize FGFR1 within mitochondria biochemically, we performed subfractionation of highly purified mitochondria from H1299 and KG1a cells. Western blot analyses of the subfractions show that both full-length FGFR1 and FOP2-FGFR1 fusion tyrosine kinase are present predominately in the mitochondrial outer membrane (Om) ( Figure 4B ). We also observed that both PDHK1 and PDHA1 are present in the mitochondrial matrix (Ma), as well as in the intermembrane space (IMS) and Om. Detailed discussion is provided in the Discussion section. To determine whether FGFR1 and FOP2-FGFR1 fusion are integrated in Om, we performed a proteinase K protection assay using purified mitochondria from H1299 and KG1a cells, respectively. Outer membrane marker Tom 40 and inner membrane marker COX IV were included as controls. As shown in Figure 4C , Tom 40 was completely digested by proteinase K treatment in both the presence and absence of Triton X-100, whereas complete digestion of COX IV by proteinase K only occurred after solubilization of mitochondria with Triton X-100 treatment. We found that, similar to Tom 40, full-length FGFR1 was completely digested by proteinase K in both the presence and absence of Triton X-100. In contrast, FOP2-FGFR1 was only partially digested by proteinase K in the absence of Triton X-100, and complete digestion of FOP2-FGFR1 was observed after solubilization of mitochondria with Triton X-100. Together, mitochondrial FGFR1 and a portion of FOP2-FGFR1 may be integrated in the mitochondrial Om, whereas the rest of mitochondrial FOP2-FGFR1 may be located inside the mitochondria, probably in the IMS, but associated with certain unknown Om proteins.
Functional PDC Can Form in Mitochondria Outside of the Matrix in Some Cancer Cells, and PDHK1 Is Commonly Phosphorylated in These Cells at Y243 by Various Oncogenic Tyrosine Kinases Furthermore, we detected PDC activity and various PDC components in the mitochondrial Om and IMS, in addition to the matrix in both H1299 and KG1a cells ( Figures 4D-4E , respectively).
These results suggest that oncogenic FGFR1 may inhibit PDC by phosphorylating PDHK1 in the Om in cancer cells. Detailed discussion is provided in the Discussion section.
We found that PDHK1 was phosphorylated at Y243 in diverse hematopoietic cancer cell lines associated with various constitutively activated tyrosine kinase mutants, including HEL (JAK2 Val617Phe mutant), KG1a (FOP2-FGFR1), K562 (BCR-ABL), and Mo91 (TEL-TrkC), whereas Y243 phosphorylation levels are relatively lower in FLT3-internal tandem duplication (ITD) mutant positive Molm14 and Mv4;11 cells, but not detected in EOL-1 (FIP1L1-PDGFRA) cells. Phosphorylation levels of PDHA1 at S293 in general correlated with PDHK1 Y243 phosphorylation levels in these leukemia cells ( Figure 5A ). Y243 phosphorylation of PDHK1 was also detected in various human solid tumor cell lines, including lung cancer H1299 (FGFR1) ( Figure 3C ) and A549 cells and breast cancer MCF-7 cells, but not breast cancer MDA-MB435 cells and prostate cancer PC3 and DU145 cells ( Figure 5A ). However, the phosphorylation levels of PDHA1 at S293 in these solid tumor cells did not correlate with PDHK1 Y243 phosphorylation levels ( Figure 5A ). Detailed discussion is provided below.
We next found that active, recombinant ABL ( Figure 5B ), JAK2 ( Figure 5C ), and FLT3 ( Figure 5D ) also directly phosphorylated PDHK1 at Y243 in the in vitro kinase assays using recombinant proteins, whereas EGFR phosphorylated PDHK1 with less efficiency ( Figure S5A ). Inhibition of BCR-ABL by imatinib, JAK2 by AG490, and FLT3-ITD by TKI258 resulted in decreased Y243 phosphorylation of PDHK1 in the pertinent human cancer cell lines ( Figure 5E ; left, middle, and right, respectively). In addition, immunoblotting results confirm the mitochondrial localization of BCR-ABL, JAK2, and FLT3 ( Figure 5F ), which are colocalized with PDHK1 and its substrate PDHA1 in mitochondria ( Figure S5B ) in the pertinent human leukemia cell lines. Moreover, western blot analyses of the subfractions of highly purified mitochondria from K562, HEL, and Molm14 leukemia cells ( Figure 5G ; left, middle, and right, respectively) show that a portion of cytoplasmic BCR-ABL and JAK2 proteins are present predominately in the matrix of mitochondria, while a portion of receptor tyrosine kinase FLT3 is present predominately in the outer membrane of mitochondria. These oncogenic tyrosine kinases are also colocalized with PDHK1 and PDHA1 in the corresponding mitochondrial subfractions in the pertinent human leukemia cell lines, where these tyrosine kinases may phosphorylate PDHK1. Consistently, PDC activity was also detected in the mitochondrial Om and IMS, in addition to the matrix in all of these cells ( Figures S5C-S5E) .
Presence of the Catalytically Less Active Mouse PDHK1 Y134F and Y239/240F Mutants in Cancer Cells Leads to Decreased Cell Proliferation under Hypoxia and Increased Oxidative Phosphorylation We next generated ''rescue'' cell lines, as previously described (Hitosugi et al., 2009) , by RNAi-mediated stable knockdown of endogenous human PDHK1 (hPDHK1) and rescue expression of FLAG-tagged mouse PDHK1 (mPDHK1) WT, or the corresponding Y134F and Y239/240F mutants ( Figure 6A ). Both FLAG-mPDHK1 WT and Y134F mutant, but not Y239/240F mutant, were phosphorylated at Y239 (corresponding to Y243 in human PDHK1 numbering) by FGFR1 in H1299 cells (A) GST-PDHK1 proteins were pulled down by beads and treated with protein tyrosine phosphatase (PTP), followed by treatment with activated rFGFR1. The beads were then incubated with recombinant PDHA1 in an in vitro kinase assay. S293 phosphorylation of PDHA1 was detected by immunoblotting (left). Right panel represents the relative intensity of the specific bands of phospho-PDHA1 E1a, which are normalized to the value of the control sample (GST-PDHK1 WT) without treatment with rFGFR1. (B) Cartoon representation of PDHK1 structure (PDB ID: 2Q8G) (Kato et al., 2007) made using Pymol (www.pymol.org). Y243 and Y244 are proximal to the ATP lid (in blue) and predicted location of ATP binding (modeled on the AMP-PNP-bound dimeric PDHK4 structure PDB ID: 2E0A in gray). Y136 is more proximal to AZD7545 (in green), which is a PDHK1 inhibitor that disrupts formation of functional pyruvate dehydrogenase complex (PDC). (C) Phosphorylation at Y243 or Y244, but not Y136, by FGFR1 leads to increased ATP binding to PDHK1. GST-PDHK1 variants were pulled down by beads from transfected 293T cell lysates and incubated with active rFGFR1, followed by incubation with [a- 
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( Figure S6A ). In addition, Y134F and Y239/240F mutants showed decreased kinase activity that led to reduced phosphorylation levels of PDHA1 at S293 in Y134F and Y239/240F rescue cells, respectively, compared to cells with mPDHK1 WT (Figure S6B ). Moreover, although hypoxia results in increased PDHK1 expression and Y243 phosphorylation levels ( Figure S6C ), endogenous hPDHK1 protein levels were not detected in diverse rescue cells under normoxia nor hypoxia, suggesting that the efficacy of hPDHK1 knockdown mediated by shRNA is not altered under hypoxia ( Figure S6D ). We also observed that, under normoxia, cells rescued with any of the mPDHK1 variants showed a comparable rate of proliferation that was greater than that of parental cells, in which endogenous hPDHK1 was stably knocked down. However, Y134F and Y239/240F rescue cells showed a significantly slower proliferation rate under hypoxic conditions than did cells rescued with mPDHK1 WT ( Figure 6B ). Moreover, compared to cells rescued with mPDHK1 WT, the Y134F and Y239/240F rescue cells and parental cells with stable knockdown of endogenous hPDHK1 had a higher rate of oxygen consumption ( Figure 6C ), an increased production of intracellular reactive oxygen species (ROS) ( Figure 6D ), and reduced lactate production ( Figure 6E ). In addition, treatment with oligomycin, a specific inhibitor of mitochondrial ATP synthase, resulted in an increased inhibition of ATP production and a decreased proliferation rate among parental control H1299 cells with stable knockdown of endogenous hPDHK1 and rescue cells expressing Y134F and Y239/ 240F mutants, compared to cells with mPDHK1 WT ( Figures  6F and 6G, respectively) . These results together suggest that cells expressing catalytically less active mPDHK1 mutants, including Y134F and Y239/240F, rely more on oxidative phosphorylation for ATP production and cell proliferation compared to cells with mPDHK1 WT.
Tyrosine Phosphorylation of PDHK1 Is Important for PDC-Mediated Pyruvate Metabolism, Probably through Inhibitory Phosphorylation of PDHA1 The pyruvate dehydrogenase complex (PDC) contributes to pyruvate decarboxylation, in which pyruvate is converted to acetyl-CoA and carbon dioxide. To determine the role of tyrosine phosphorylation of PDHK1 in regulation of PDC activity, we performed a pyruvate consumption experiment using highly purified mitochondria. We found that mitochondria isolated from rescue cells expressing mPDHK1 Y239/240F mutant show a significantly increased pyruvate consumption rate, compared to mitochondria isolated from WT rescue cells ( Figure 6H ). Moreover, we examined the PDC activity by assessing the rate of PDC-mediated conversion of pyruvate to CO 2 . As shown in Figure 6I , isolated mitochondria from cells expressing mPDHK1 Y239/240F mutant have a significantly increased rate of transforming 14 C-labeled pyruvate to 14 C-labeled CO 2 , compared to mitochondria isolated from WT rescue cells. These data suggest an important role for tyrosine phosphorylation of PDHK1 in regulation of PDC activity, probably by phosphorylating PDHA1. We next sought to determine the role of PDHA1 in PDHK1-regulated cancer cell metabolism. As shown in Figure 7A , expression of PDHA1 WT or an active, phospho-deficient mutant S293A in H1299 rescue cells of either mPDHK1 WT or Y239/ 240F mutant resulted in an increased O 2 consumption rate. In contrast, mPDHK1 WT rescue cells expressing a phosphomimetic, catalytically less active form of PDHA1 (S293D) showed less increase in O 2 consumption compared to cells expressing PDHA1 WT or S293A mutant, whereas expression of PDHA1 S293D mutant, but not PDHA1 WT or S293A mutant, resulted in a significant decrease in O 2 consumption in H1299 rescue cells of mPDHK1 Y239/240F. Furthermore, expression of PDHA1 WT, S293A, or S293D mutants in rescue cells of mPDHK1 Y239/240F did not affect cell proliferation under normoxia. However, expression of PDHA1 S293D mutant, but not WT or S293A mutant, resulted in decreased sensitivity of mPDHK1 Y239/240F rescue cells to hypoxia in regard to cell proliferation ( Figure 7B ). Moreover, rescue cells of mPDHK1 Y239/240F transfected with PDHA1 S293D mutant showed increased lactate production ( Figure 7C ) and decreased sensitivity to the treatment with oligomycin, an inhibitor of ATP synthase, in regard to ATP production and cell proliferation ( Figures  7D and 7E, respectively) , compared to cells transfected with PDHA1 WT or S293A mutant. These data together with data presented in Figure 6 suggest that rescue expression of mPDHK1 Y239/240F makes cells rely more on oxidative phosphorylation, whereas expression of the inactive, phospho-mimetic PDHA1 S293D mutant attenuates such a metabolic switch.
Expression of mPDHK1 Y239/240F Mutant in Cancer Cells Leads to Reduced Tumor Growth in Xenograft Nude Mice
We next performed xenograft experiments in which nude mice were injected with FLAG-mPDHK1 WT and Y239/240F rescue H1299 cells ( Figure S7A ). Ten million cells each were injected (FLAG-mPDHK1 WT rescue cells on the left flank and Y239/ 240F cells on the right flank; n = 10), and the mice were monitored for tumor growth over a 5 week time period. The masses of tumors derived from Y239/240F rescue cells were significantly reduced compared to those of tumors formed by FLAGmPDHK1 WT rescue cells ( Figures 7F and 7G ).
DISCUSSION
Our finding that tyrosine phosphorylation activates PDHK1 may, at least in part, explain the functional attenuation of mitochondria in cancer cells . This could represent (D and E) FGFR1-dependent phosphorylation at Y136 (D), Y243, and Y244 (E) promotes PDHK1 binding to PDC. GST-PDHK1 variants were pulled down by beads and incubated with active rFGFR1, followed by incubation with whole-cell lysates of 293T cells. The bound PDC E2 protein and PDHA1 E1a proteins were detected by immunoblotting. Upper panel shows immunoblotting results from one representative experiment. Lower panel shows summarized results from two independent experiments that represent the relative intensity of the specific bands of PDHA1 E1a and PDC E2 that bind to PDHK1, which are normalized to the value of control sample without treatment with rFGFR1. The error bars represent mean values ± SD. a common, short-term molecular mechanism underlying the Warburg effect in both leukemias and solid tumors, in addition to the chronic changes, which include upregulation of PDHK1 gene expression to achieve mitochondrial inhibition, believed to be regulated by transcription factors including Myc and HIF-1.
An interesting observation is that a fraction of receptor tyrosine kinases, including FGFR1 and FLT3, are predominantly present in the mitochondrial Om, whereas a fraction of cytoplasmic tyrosine kinases BCR-ABL and JAK2 are found in the mitochondrial matrix. However, we also observed that a fraction of cytoplasmic fusion tyrosine kinase FOP2-FGFR1 is predominantly present in the mitochondrial Om. Surprisingly, the results of proteinase protection assay suggest that FGFR1 may be integrated in the Om of mitochondria, while FOP2-FGFR1 may also be presented inside the mitochondria, probably in the IMS but associated with certain Om proteins to demonstrate 
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Tyrosine Phosphorylation Activates PDHK1 a predominant sublocalization to the mitochondrial Om. These findings together suggest a new role for oncogenic tyrosine kinases which may be localized to mitochondria and function by phosphorylating mitochondrial proteins. FOP2-FGFR1, BCR-ABL, FLT3-ITD, and JAK2 V617F are constitutively active and ligand independent. We detected mitochondrial full-length FGFR1 as tyrosine phosphorylated in H1299 cells, suggesting that mitochondrial FGFR1 has a basal level of tyrosine kinase activity and may be ligand independent (S.K. and J.C., unpublished data). Further studies are warranted to determine the regions of these oncogenic tyrosine kinases for mitochondrial localization as well as the molecular mechanism underlying the differential mitochondrial sublocalization and contribution to mitochondrial biology and cancer cell metabolism. We also observed that in the tested human cancer cells, both PDHK1 and PDHA1 are present in Om and IMS, and in some cases the inner membrane, in addition to the mitochondrial matrix. The Om sublocalization may be due to binding of PDHK1 and PDHA1 to some outer membrane proteins. In fact, we observed that PDHK1 interacts with FGFR1 WT that is catalytically active, while the PDHK1-FGFR1 interaction is decreased when PDHK1 is coexpressed with a FGFR1 kinase dead mutant (KD), suggesting that the tyrosine kinase activity may be required for the interaction between FGFR1 and PDHK1 ( Figure S7B ). Moreover, PDC activity and various PDC components were detected in the mitochondrial outer membrane and intermembrane space, in addition to the matrix in all of the tested cancer cell lines ( Figures 4D, 4E , and S5C-S5E). This suggests that PDC can be functionally formed outside of the matrix. Moreover, cancer cells with oncogenic tyrosine kinases in the Om, including H1299 (FGFR1), KG-1a (FOP2-FGFR1), and Molm 14 (FLT3-ITD), show relatively low levels of PDC activity in the Om compared to the matrix, whereas cells with oncogenic TKs in the matrix, including K562 (BCR-ABL) and HEL (JAK2 V617F), demonstrate lower PDC activity in the matrix compared to the Om. These data suggest that, although diverse oncogenic TKs differentially localize to different compartments of mitochondria in cancer cells, they may regulate cancer metabolism in a similar way by inhibiting PDC activity in the correlated mitochondrial compartments. However, how the attenuated PDC activity in these cells contributes to cancer cell metabolism may vary due to, for example, the different mitochondrial compartmentation of PDC and its products NADH and acetyl-coA. These findings also warrant further studies to determine how the functional PDC activity outside of the matrix contributes to pyruvate decarboxylation and consequently mitochondrial function and metabolism.
The structural mechanisms by which phosphorylation affects PDHK1 function are still to be determined, but the proximity of Y243 and Y244 suggests altered dynamics for the ATP lid and, consequently, ADP/ATP-binding properties. It will be important to further investigate the atomic-level effects of phosphorylation of these residues using structural biology techniques. It is interesting that PDHA1 was detected to be S293 phosphorylated in EOL-1, MDA-MB435, PC3, and DU145 cells that have nondetectable PDHK1 Y243 phosphorylation. Since PDHK1 WT proteins treated with PTP still maintain basal levels of kinase activity (Figure 2A ), this may suggest that these cells might rely on PDHK1 protein expression levels for PDHA1 phosphorylation more than tyrosine phosphorylation-dependent activation of PDHK1. It is also possible that the pyruvate dehydrogenase phosphatase (PDP) activity, which functions by dephosphorylating PDHA1, is relatively low in these cells, or isoforms of PDHK other than PDHK1 may be responsible for PDHA1 phosphorylation in these cells. In contrast, MCF-7 cells have high protein expression levels of PDP1 ( Figure S7C ), which explains why MCF-7 cells have high levels of PDHK1 phosphorylation but the phosphorylation level of PDHA1 is low.
Our findings suggest that PDHK1 may serve as a therapeutic target in cancer treatment, such that inhibition of PDHK1 may affect cancer cell metabolism and cause tumor regression. These findings are consistent with previous observations that targeting PDHK by small molecule inhibitor DCA attenuates cancer cell proliferation and tumor growth using A549 lung cancer cells (Bonnet et al., 2007) . However, the authors reported that targeting PDHK2 by specific siRNA, but not the control scrambled siRNA, mimics DCA effects on A549 cells. Further studies to identify distinct roles of different PDHK isoforms in cancer cell metabolism and tumor growth are warranted.
We previously reported that oncogenic tyrosine kinases including FGFR1 phosphorylate and inhibit PKM2 to regulate cancer metabolism (Hitosugi et al., 2009 ). Both tyrosine phosphorylation-dependent regulation of PKM2 and PDHK1 contributes to the metabolic switch from oxidative phosphorylation to aerobic glycolysis in cancer cells. Interestingly, we found that Y105 phosphorylation of PKM2 is important in regulation of PDHK1 gene expression; the mRNA and protein levels of PDHK1 are significantly decreased in FGFR1-expressing H1299 lung cancer cells with stable knockdown of endogenous human PKM2 and rescue expression of mouse PKM2 Y105F mutant, compared to cells expressing mPKM2 WT (T.H. and J.C., unpublished data) . This in part explains the decreased PDHK1 protein levels in H1299 cells with shRNA-mediated long-term knockdown of FGFR1 ( Figure 3D ). These findings suggest a dual role for FGFR1 in regulation of PDHK1 in cancer metabolism, which consists of a long-term mechanism by which FGFR1 may phosphorylate PKM2 to promote PDHK1 gene expression and a short-term mechanism by which FGFR1 activates PDHK1 through tyrosine phosphorylation at multiple sites. Y105 phosphorylation of PKM2, which is involved in FGFR1-regulated PDHK1 expression, appears to be an upstream event that precedes FGFR1-dependent phosphorylation and activation of PDHK1 in cancer cell metabolism. 
EXPERIMENTAL PROCEDURES
Immunofluorescence Microscopy, TEM, and Mitochondrial Subfractionation Assays For immunofluorescence microscopy, cells seeded on glass coverslips were stained for mitochondria with MitoTracker Red CMXRos (Invitrogen), followed by fixation in PHEMO buffer and then blocked with 10% goat serum (Invitrogen). Cells were incubated with FGFR1 primary antibody in PBS containing 5% goat serum, followed by incubation with goat anti-rabbit IgG conjugated with Alexa Fluor 488 (Invitrogen) in PBS with 5% goat serum. Cells were washed in PBS, mounted, and imaged on a Zeiss LSM510 META confocal microscope. Immunogold labeling of FGFR1 was performed as previously described (Yi et al., 2001) . Mitochondrial subfractionation was performed as described by She et al. (2011) .
Mitochondrial Pyruvate Consumption and [1-14 C]-Pyruvate Conversion Assays Pyruvate utilization by mitochondria was measured as described (Olsen, 1971) . Briefly, isolated mitochondria were mixed with the mitochondria resuspension buffer, followed by centrifugation and pyruvate assay. The assay was carried out in reaction buffer containing 20 mM HEPES (pH 7.2), 0.05% BSA, 20 mM NADH, and recombinant LDH (0.01 mg/ml). Pyruvate concentration was determined by measuring the decrease in fluorescence from the oxidation of NADH with a spectrofluorometer (ex: 340 nm; em: 460 nm). The [1-14 C]-pyruvate conversion assay was performed as described (Pezzato et al., 2009) . Briefly, 14 CO 2 production through PDC was measured using isolated mitochondria (1 mg) in the mitochondria resuspension buffer (1 ml) containing [1-14 C]-pyruvate (0.1 mCi/ml). The incubation mixture was placed at the bottom of a vial with a rubber stopper and maintained in agitation. The 14 CO 2 produced during incubation was trapped by hyamine hydroxide placed in an eppendorf tube in the vial. The reaction was blocked with 0.5 ml of 50% TCA after 1 hr. Twenty minutes after the TCA injection, all the samples in hyamine hydroxide were transferred to minivials together with 5 ml of scintillator liquid, and radioactivity was assayed on a scintillation counter. The results were normalized based on mitochondrial protein levels assayed by Bradford assay using BSA as a standard.
Xenograft Studies
Nude mice (nu/nu, female 6-8 weeks old, Harlan Labs) were subcutaneously injected with 1 3 10 7 H1299 cells stably expressing mPDHK1 WT and Y239/ 240F mutant in conjunction with stable knockdown of endogenous PDHK1 on the left and right flanks, respectively. Tumor formation was assessed every 2 to 3 days. Tumor growth was recorded by measuring two perpendicular diameters of the tumors over a 5 week time course using the formula 4p/ 3 3 (width/2) 2 3 (length/2). The tumors were harvested and weighed at the experimental endpoint, and the masses of tumors (g) in both flanks of each mouse were compared. Statistical analyses were performed using a paired Student's t test.
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